Dr Lee, one of the Singapore O&G founders bought SGD65k of shares last week. This is part of a string of insider purchases over the last 12 months which suggests that the company is undervalued.
As I previously
mentioned, Singapore O&G net profit is likely to see at least 10-12% earnings growth over the next five years because of its strategy to expand its women’s healthcare and paediatrics practice.
| |
Buyer |
Shares bought |
Value (SGD) |
Implied share price (SGD) |
| Jul-2018 |
Dr Lee Keen Whye |
193,500 |
65,480 |
0.34 |
| Feb-2018 |
Dr Joyce Lim |
100,000 |
38,750 |
0.39 |
| Aug-2017 |
Dr Beh Suan Tiong |
100,000 |
47,700 |
0.48 |
| Aug-2017 |
Dr Heng Tung Lan |
100,000 |
47,500 |
0.48 |
Singapore O&G is currently trading at a 18x trailing P/E which seems like a fair price for a healthcare company which is less exposed to economic cycles.
In ......
